Brief: Herantis Pharma Says Phase 1b Biomarker Data Show Clear Evidence Of Biological Response To HER-096 In Parkinson’s Patients
07/01/2026 18:23
Jan 7 (Reuters) - Herantis Pharma Oyj HRTIS.HE: HERANTIS PHARMA - PHASE 1B BIOMARKER DATA SHOW CLEAR EVIDENCE OF BIOLOGICAL RESPONSE TO HER-096 IN PEOPLE WITH PARKINSON'S DISEASE Source text: ID:nGNX3xVzGV Further company coverage: HRTIS.HE (((( Reuters.Briefs@thomsonreuters.com ;));))